Skip to content
10-Q

Quarterly Report

Sunshine Biopharma Inc. SBFM SBFMW

0001683168-25-003701

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 15, 2025 4.56M sh
Shares Diluted Q1 2025 · Mar 31, 2025 2.7M sh
Shares Diluted Q1 2025 · Mar 31, 2024 641.31K sh
Stock Repurchased Q1 2025 · Mar 31, 2025 $0
Stock Repurchased Q1 2025 · Mar 31, 2024 $3.14M
Current Liabilities Q1 2025 · Mar 31, 2025 $5.76M
Current Liabilities Q1 2025 · Dec 31, 2024 $6.31M
Total Liabilities Q1 2025 · Mar 31, 2025 $6.48M
Total Liabilities Q1 2025 · Dec 31, 2024 $7.06M
Current Assets Q1 2025 · Mar 31, 2025 $24.48M
Current Assets Q1 2025 · Dec 31, 2024 $25.97M
Total Assets Q1 2025 · Mar 31, 2025 $29.19M
Total Assets Q1 2025 · Dec 31, 2024 $30.56M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.44
Eps Diluted Q1 2025 · Mar 31, 2024 −$2.00
Capex Q1 2025 · Mar 31, 2024 $62.94K
Operating Cash Flow restated Q1 2025 · Mar 31, 2024 −$3.19M
Stockholders Equity Q1 2025 · Mar 31, 2024 $24.82M
Stockholders Equity Q1 2025 · Dec 31, 2023 $21.21M
Eps Basic Q1 2025 · Mar 31, 2024 −$2.00
Sga Expense Q1 2025 · Mar 31, 2024 $3.7M
Rd Expense Q1 2025 · Mar 31, 2024 $222.03K
Net Income Q1 2025 · Mar 31, 2024 −$1.28M
Operating Income Q1 2025 · Mar 31, 2024 −$1.35M
Gross Profit Q1 2025 · Mar 31, 2024 $2.35M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $5.19M
Revenue Q1 2025 · Mar 31, 2024 $7.54M